Last reviewed · How we verify
Drug: Pegylated rhG-CSF: 100µg/kg
Drug: Pegylated rhG-CSF: 100µg/kg is a Pegylated cytokine; G-CSF receptor agonist Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Chemotherapy-induced neutropenia (CIN), Severe congenital neutropenia, Idiopathic or cyclic neutropenia.
Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.
Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts. Used for Chemotherapy-induced neutropenia (CIN), Severe congenital neutropenia, Idiopathic or cyclic neutropenia.
At a glance
| Generic name | Drug: Pegylated rhG-CSF: 100µg/kg |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Pegylated cytokine; G-CSF receptor agonist |
| Target | G-CSF receptor (CSF3R) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Hematology |
| Phase | Phase 3 |
Mechanism of action
G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells, promoting their maturation into functional neutrophils. Pegylation extends the drug's half-life by reducing renal clearance and increasing circulation time, allowing for less frequent dosing compared to non-pegylated G-CSF. This results in sustained elevation of neutrophil counts, reducing infection risk in patients with chemotherapy-induced neutropenia or other neutropenic conditions.
Approved indications
- Chemotherapy-induced neutropenia (CIN)
- Severe congenital neutropenia
- Idiopathic or cyclic neutropenia
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
- Splenomegaly
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: Pegylated rhG-CSF: 100µg/kg CI brief — competitive landscape report
- Drug: Pegylated rhG-CSF: 100µg/kg updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about Drug: Pegylated rhG-CSF: 100µg/kg
What is Drug: Pegylated rhG-CSF: 100µg/kg?
How does Drug: Pegylated rhG-CSF: 100µg/kg work?
What is Drug: Pegylated rhG-CSF: 100µg/kg used for?
Who makes Drug: Pegylated rhG-CSF: 100µg/kg?
What drug class is Drug: Pegylated rhG-CSF: 100µg/kg in?
What development phase is Drug: Pegylated rhG-CSF: 100µg/kg in?
What are the side effects of Drug: Pegylated rhG-CSF: 100µg/kg?
What does Drug: Pegylated rhG-CSF: 100µg/kg target?
Related
- Drug class: All Pegylated cytokine; G-CSF receptor agonist drugs
- Target: All drugs targeting G-CSF receptor (CSF3R)
- Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology; Hematology
- Indication: Drugs for Chemotherapy-induced neutropenia (CIN)
- Indication: Drugs for Severe congenital neutropenia
- Indication: Drugs for Idiopathic or cyclic neutropenia